CNTX

Minai-Azary Jennifer Lynn

Known title: Chief Financial OfficerCIK: 0001844398

Minai-Azary Jennifer Lynn's purchase track record

How the stock did after each of Minai-Azary Jennifer Lynn's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 3 since August 17, 2022
Stock higher 6 months later
67%
3 months: 33%
Median 6-month return
+58.1%
3 months: -16.4%
Beat the S&P 500
67%
median +43.6% vs. index
PurchaseStockAmount3 months6 months
6/6/2025CNTX$25K+23.5%+58.1%
12/16/2022CNTX$19K-16.4%+74.3%
8/17/2022CNTX$27K-33.3%-53.6%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

CNTX appears on Yahoo's recent strong negative rating lists. Yahoo listed Context Therapeutics in its strong negative rating lists for October 13 and October 15. The inclusion reflects recent analyst concerns about the company's outlook. The stock is currently trading with a low RSI and near its identified support level, which aligns with the negative sentiment.

this person other insiders at CNTX

Transaction History

CNTX▲ Buy$25K
CNTX▲ Buy$19K
CNTX▲ Buy$27K

We use analytics to understand how market-wall is used. No personal data is sold.